^
Association details:
| Biomarker: | HER-2 overexpression + HER-2 amplification |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors
Published date:
10/04/2023
Excerpt:
We assessed pertuzumab + trastuzumab in a tissue-agnostic cohort of adult patients with human epidermal growth factor receptor 2 (HER2)-amplified and/or -overexpressed and/or -mutated solid tumors...Pertuzumab + trastuzumab showed activity in various HER2-amplified and/or -overexpressed tumors...
DOI:
10.1200/JCO.22.02636
Trial ID:
